Related references
Note: Only part of the references are listed.Antimicrobial Susceptibility Patterns for Recent Clinical Isolates of Anaerobic Bacteria in South Korea
Yangsoon Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005-2007)
David R. Snydman et al.
CLINICAL INFECTIOUS DISEASES (2010)
German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study
Harald Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
Joseph S. Solomkin et al.
SURGICAL INFECTIONS (2010)
Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections
Joseph Solomkin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Moxifloxacin for the Treatment of Patients with Complicated Intra-abdominal Infections (the AIDA Study)
G. Weiss et al.
JOURNAL OF CHEMOTHERAPY (2009)
Intra-Abdominal Infections
John E. Mazuski et al.
SURGICAL CLINICS OF NORTH AMERICA (2009)
Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens
Gary E. Stein et al.
ANAEROBE (2008)
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections:: Emerging resistance to carbapenems
Chia-Ying Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess
Andreas D. Rink et al.
CLINICAL DRUG INVESTIGATION (2008)
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study
Christopher Lucasti et al.
CLINICAL THERAPEUTICS (2008)
Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece
Joseph Papaparaskevas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents
Diane M. Citron et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
National survey on the susceptibility of Bacteroides fragilis group:: Report and analysis of trends in the united states from 1997 to 2004
D. R. Snydman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis
H. Stass et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections
Mark A. Malangoni et al.
ANNALS OF SURGERY (2006)
In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections
EJC Goldstein et al.
ANAEROBE (2006)
In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections
EJC Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Anaerobes: Antibiotic resistance, clinical significance, and the role of susceptibility testing
David W. Hecht
ANAEROBE (2006)
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data
T Babinchak et al.
CLINICAL INFECTIOUS DISEASES (2005)
In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections
CE Edmiston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy
EJC Goldstein et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Emergence of fluoroquinolone resistance among Bacteroides species
Y Golan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns
KE Aldridge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Microbiology of polymicrobial abscesses and implications for therapy
I Brook
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and β-lactams
J Behra-Miellet et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
In vitro activities of newer quinolones against Bacteroides group organisms
DR Snydman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents
R Horn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria
N Kleinkauf et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
In vitro activity of moxifloxacin against 179 strains of anaerobic bacteria found in pulmonary infections
HM Wexler et al.
ANAEROBE (2000)
Antimicrobial resistance and clinical outcome of bacteroides bacteremia: Findings of a multicenter prospective observational trial
MH Nguyen et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
